1547P Predictors of short-, medium-, and long-term survival with limited stage small cell lung cancer in the real-world

Immune checkpoint inhibitors (ICIs) added to first-line small cell lung cancer (SCLC) management increases the importance of understanding baseline factors/treatment contributing long-term survival. While reported ICI trials have focused on extensive stage disease, active investigate possible benefits adding ICIs in treatment limited (LS) SCLC. Here we examine factors associated with real-world survival LS-SCLC. Retrospective cohort study Manitobans aged >18 years who received chemotherapy cytologically confirmed LS-SCLC diagnosed 2004–2017. Descriptive statistics compared and by duration [short (<6 months [m]), medium (6-24m), long (>24 m)]. Differences were considered significant when P-values ≤0.05. Overall was defined as time between first death or end follow-up (August 31, 2020). Survival assessed using Kaplan-Meier methods Cox proportional hazards models. Real-world analysis included 304 patients. Long-term survivors made up 39.1% (n=119) at diagnosis more likely be younger, performance status ECOG 0, normal lactate dehydrogenase, sodium, haemoglobin (each p<0.03). Complete/partial response for short-, medium-, 41.4%, 73.1%, 79.8%, respectively (p<0.001). Short-term less receive cisplatin palliate radiotherapy (RT) no RT. Prophylactic cranial irradiation (PCI) used 10.3%, 30.1%, 64.7% (p<0.001), respectively. Five-year observed 18% modelling showed that only (ECOG 1-2 HR 1.39 [1.05-1.84], 3-4 1.69 [1.09-2.63]) PCI (HR 0.45 [0.35-0.58]) independently Only a 6m landmarked model. In patients treated chemotherapy, survive >24 least five years. Traditional prognostic are survival, receipt having most impact.